Abstract: The invention provides a circuit system for driving a high-intensity discharging lamp, comprising a boosting circuit, an ignition coil circuit and a clamp circuit. The boosting circuit includes a first transformer and a first switch, in which the primary of the first transformer receives an input power, the secondary of the first transformer produces a boosting DC voltage, and the first switch is connected to the first transformer to control turning-on and turning-off of the first transformer. The ignition coil circuit is connected to the boosting circuit for converting the boosting DC voltage into a switching AC voltage to drive a load. The clamp circuit is connected to the boosting circuit and the ignition coil circuit for directing energy, reflected from the secondary of the first transformer to the primary of the first transformer, to the secondary of the first transformer as the first switch is turned off.

Abstract: Biomacromolecules such as proteins are inactivated by hydrophobic ANSA derivatives of the formula: wherein R1 and R2 are hydrophobic or affinity groups and R3 is selected from the group consisting of aminoacyl groups and peptidyl groups upon nitrosation. ANSA derivatives can be designed to selectively kill tumor cells and various pathogens, including bacteria, viruses, and fungi.

Abstract: Synthetic methods and intermediates useful in the preparation of lactone containing compounds such as discodermolide and compounds which mimic the chemical or biological activity of discodermolide are provided.

Abstract: A software operation modeling device (100) includes: a stack information recording unit (120), an end information recording unit (150), a stack difference information generation unit (130) for generating information for generating stack difference information by concatenating a call stack upper node of stack information with information until the end information is detected by using the end information recorded by the end information recording unit (150), and a model generation unit (140) for generating a software operation model from the stack difference information.

Abstract: An object of the present invention is to provide a method for the online management of medical record forms, which can provide web screens through terminals to enable doctors, nurses, pharmacists, or the like to immediately online input and read a variety of information created upon treating and caring for patients in a hospital, and can add, modify, delete or manage various medical record forms provided on the web screens and images inserted into records.

Abstract: The invention provides novel inhibitors of protein translation initiation and inhibitors of eIF4F activity that can increase chemosensitivity or diminish or reverse chemoresistance in growth transformed cells and thereby reduce hyperproliferative conditions, such as cancer progression, in select patient populations having particular tumor genotypes. The invention also provides methods which target translation initiation controls in growth-transformed cells, such as tumor subtypes with altered expression of a gene activity, including the human akt, bcl-2, eIF4E, eIF4A or PTEN activities, to restore drug sensitivity in vivo in a genotype selective manner. In one aspect, the inhibitors of translation initiation of the invention are rocaglates, i.e., cyclopenta[b]benzofurons, which increases chemosensitivity or diminishes or reverses chemoresistance either alone or in combination, additively or synergistically, with other agents that alter growth or death.

Abstract: Disclosed herein are bio-markers for diagnosing diabetic retinopathy, a use of proteins, whose expression level down-regulated or up-regulated in the tears of a non-proliferative diabetic retinopathy (NPDR) patient, as bio-markers for diagnosing diabetic retinopathy, and a composition and kit for diagnosing diabetic retinopathy comprising antibodies against said proteins.

Abstract: Global gene expression patterns have been characterized in normal and cancerous human cells using serial analysis of gene expression (SAGE). Cancer cell-specific, cell-type specific, and ubiquitously expressed genes have been identified. This information can be used to provide combinations of cell type- and cancer-specific gene probes, as well as methods of using these probes to identify particular cell types, screen for useful drugs, reduce cancer-specific gene expression, standardize gene expression, and restore function to a diseased cell or tissue.

Abstract: Nano-sized lipid vesicles with tailored properties are used as building blocks to generate lipid tubules between two glass surfaces. The tubules formed not only have defined orientation, width, and length, but they can also grow to be as long as 13 mm under ambient conditions, without externally supplied flow, temperature control, or catalyzing agents. The tubule membrane and its internal aqueous content can be manipulated by controlling the combination of different vesicle's lipid composition and aqueous entrapment. This self-assembly process opens up new pathways for generating complicated and flexible architectures for use in biocompatible molecular and supramolecular engineering. Aspects of the invention generate, for example, tubules encapsulated with siRNA, tubules with multiple branches, and polymerized fluorescent tubules in a single-throughput self-assembly process.

Abstract: This invention concerns a process to convert a hydroxyl group (bold in R3C—OH) in a tigliane-type compound to a hydrogen (bold in R3C—H) to obtain deoxytigliane-type compounds or structural or functional analogs thereof. The process has wide application particularly to produce specific biologically active compounds in quantity for use as pharmaceuticals. In particular the process can be used to convert phorbol to a 12-deoxytigliane (prostrating which is a therapeutic lead for the treatment of AIDS. New compositions of matter are also disclosed.

Abstract: The subject invention concerns materials and methods for gene therapy. One aspect of the invention pertains to vectors which can be used to effect genetic therapy in animals or humans having genetic disorders where expression of high levels of a protein of interest are required to treat or correct the disorder. The subject invention also pertains to methods for treating animals or humans in need of gene therapy to treat or correct a genetic disorder. The materials and methods of the invention can be used to provide therapeutically effective levels of a protein that is non-functional, or that is absent or deficient in the animal or human to be treated. In one embodiment, the materials and methods can be used to treat alpha-1-antitrypsin deficiency.

Abstract: A method of determining a subsurface temperature in a body of water is disclosed. The method includes obtaining surface temperature anomaly data and surface height anomaly data of the body of water for a region of interest, and also obtaining subsurface temperature anomaly data for the region of interest at a plurality of depths. The method further includes regressing the obtained surface temperature anomaly data and surface height anomaly data for the region of interest with the obtained subsurface temperature anomaly data for the plurality of depths to generate regression coefficients, estimating a subsurface temperature at one or more other depths for the region of interest based on the generated regression coefficients and outputting the estimated subsurface temperature at the one or more other depths. Using the estimated subsurface temperature, signal propagation times and trajectories of marine life in the body of water are determined.

Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having O06-mediated diseases, or to diagnose % Qmediated diseases.

Abstract: The present invention provides a novel RNA, designated herein as the “HSR1” (Heat Shock RNA), and its use together with translation elongation factor eEF1A in activation of heat shock transcription factor HSF. The invention further provides the use of HSR1 for generation of novel therapeutics for the treatment of various diseases in animals and for generation of stress-resistant plants.

Abstract: A thermal conduction switch includes a thermally-conductive first member having a first thermal contacting structure for securing the first member as a stationary member to a thermally regulated body or a body requiring thermal regulation. A movable thermally-conductive second member has a second thermal contacting surface. A thermally conductive coupler is interposed between the first member and the second member for thermally coupling the first member to the second member. At least one control spring is coupled between the first member and the second member. The control spring includes a NiTiFe comprising shape memory (SM) material that provides a phase change temperature <273 K, a transformation range <40 K, and a hysteresis of <10 K. A bias spring is between the first member and the second member. At the phase change the switch provides a distance change (displacement) between first and second member by at least 1 mm, such as 2 to 4 mm.

Abstract: The present invention provides methods and devices for isolating cells from a subject by circulating the subject's body fluid over an affinity moeity coupled matrix to isolate isolate cells from a subject either ex vivo or in vivo. One aspect of the invention is directed to connecting a subject to a system capable of circulating the subject's body fluid through an affinity moiety coupled matrix, such that the affinity moiety coupled matrix is capable of binding to and extracting target cells from the body fluid, and then eluting the target cells from the affinity moiety. Another aspect of the invention is directed to the apparatus for isolating cells from a subject, comprising a blood circulation system with an arterial side blood circuit for extracting blood and flowing the blood over an affinity moiety coupled matrix that binds to and extracts target cells and a venous side blood circuit for returning the blood to the patient.

Abstract: A radio frequency identification (RFID) tag is provided that prevents a recognition error of the RFID tag due to the occurrence of a shadow region. The RFID tag includes a first tag performing communication with an RFID reader and a second tag connected to the first tag and suitable for use with a different communication type from the first tag. Thus, when information stored in the first tag can not be read, the second tag is activated and externally transmits information and when information stored in the first tag can be read, the second tag is 1o deactivated and does not externally transmit information. A communication method of an RFID system including an RFID reader communicating with an RFID tag is also provided.

Abstract: This invention provides an interferometer for detecting analyte in a microfluidic chip. The device maintains a stable temperature at the chip with variation of no more than 5 microdegrees C. and/or no more than 20 microdegrees C. in the medium through which the optical train travels from a source of coherent light to the chip when ambient temperature changes up to 5 degrees centigrade over five minutes. The device comprises thermally isolated compartments that hinder heat transfer from one part of the instrument to another and temperature regulators that regulate temperature of the chip and the optical train compartment as a function of temperatures at the chip, in the compartment, and ambient. The invention also provides a microfluidic system that can deliver 1 microliter of sample to a sensing area with loss in analyte concentration of less than 5%. The device has an adaptor that mates with a micropipette tip and short channel length and small volume to the sensing area.

Abstract: A system for controlling abnormal traffic based on a fuzzy logic includes: an intrusion detection module for analyzing packets incoming from a network interface by means of a membership function defined based on a specific period of time, and outputting a fuzzy value representing a degree of a port scan attack; a fuzzy control module for recognizing the degree of the port scan attack based on the fuzzy value and outputting a control signal for traffic control according to the recognized degree of the port scan attack; and an intrusion blocking module for receiving the control signal and controlling the traffic with the network interface.

Abstract: The present invention provides methods for systematically identifying genes, proteins and/or related pathways that regulate or indicative of cell phenotypes. The present invention further provides methods for manipulating the identified genes, proteins and/or pathways to engineer improved cell lines and/or to evaluate or select cell lines with desirable phenotypes.